Study protocol and rationale for a randomized double-blinded crossover trial of PHENTERMINE (cas 122-09-8)-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa

Add time:09/25/2019    Source:sciencedirect.com

IntroductionBulimia nervosa (BN) and binge eating disorder (BED) are associated with severe psychological and medical consequences. Current therapies are limited, leaving up to 50% of patients symptomatic despite treatment, underscoring the need for additional treatment options. Qsymia, an FDA-approved medication for obesity, combines phentermine and topiramate ER. Topiramate has demonstrated efficacy for both BED and BN, but limited tolerability. Phentermine is FDA-approved for weight loss. A rationale for combined phentermine/topiramate for BED and BN is improved tolerability and efficacy. While a prior case series exploring Qsymia for BED showed promise, randomized studies are needed to evaluate Qsymia's safety and efficacy when re-purposed in eating disorders. We present a study protocol for a Phase I/IIa single-center, prospective, double-blinded, randomized, crossover trial examining safety and preliminary efficacy of Qsymia for BED and BN.

We also recommend Trading Suppliers and Manufacturers of PHENTERMINE (cas 122-09-8). Pls Click Website Link as below: cas 122-09-8 suppliers

Prev:Case ReportParadoxical topiramate-induced hyperphagia successfully treated with PHENTERMINE (cas 122-09-8) in a woman with migraine
Next:Electrochemical aptasensor for Sulfadimethoxine (cas 122-11-2) detection based on the triggered cleavage activity of nuclease P1 by aptamer-target complex)